Pharmacological profile and nature of the drug
Oprelvekin is a high-tech medicinal product that is pharmacologically classified as a recombinant growth factor. More specifically, it is a laboratory-synthesized analogue of natural human interleukin-11 (IL-11).
In the human body, interleukins play the role of vital signaling molecules regulating numerous processes, but this specific cytokine functionally acts as a potent thrombopoietic growth factor. This means its primary role in pharmacotherapy is the targeted management of hematopoiesis, specifically the branch responsible for platelet formation. The use of recombinant technology allows this protein to be produced in quantities sufficient to achieve a pronounced therapeutic effect in patients requiring emergency support of the hematopoietic system.
Mechanism of action: from stem cell to platelet
The mechanism of action of oprelvekin is implemented across several successive stages of blood cell development, ranging from the earliest precursors to mature forms.
- Direct stimulation of hematopoietic stem cell proliferation. This is a fundamental process in which basic, undifferentiated bone marrow cells begin to divide actively, creating the necessary cell pool for further hematopoiesis.
- Effect on megakaryocyte progenitor cells. The drug directs the development of the dividing cell pool specifically along the megakaryocytic pathway.
- Induction of megakaryocyte maturation. Under the influence of recombinant interleukin-11, these bone marrow cells pass through all stages of their development more rapidly.
The logical result of this multi-step cascade of reactions is a massive release of blood platelets. As a result, the patient's systemic circulation shows a reliable increase in the platelet count, which is critical for maintaining normal blood coagulation.
Clinical application in oncology
In clinical practice, oprelvekin has strict indications associated with the treatment of oncological diseases and mitigating the consequences of aggressive therapy.
The drug is prescribed exclusively to adult patients. A crucial criterion for its use is the presence of non-myeloid malignancies in the patient. This means the tumor process must not originate from the myeloid lineage of hematopoiesis.
The main clinical niche for oprelvekin is the period following courses of myelosuppressive chemotherapy. As is well known, many anticancer drugs have a toxic effect on the bone marrow, suppressing its function. Oprelvekin is administered in clinical situations where the patient is diagnosed with a high risk of severe thrombocytopenia—a condition in which the platelet count drops so low that there is a danger of massive hemorrhage. Timely administration of this growth factor protects the patient and allows planned chemotherapy cycles to be conducted safely.
Adverse reactions
Like any drug that actively interferes with the body's systemic processes, oprelvekin has a number of side effects. For ease of study, they are typically classified by organ systems:
- General systemic reactions: patients frequently complain of pronounced asthenia (asthenia — general weakness), chills, and increased nervousness.
- Gastrointestinal tract (GIT): therapy may be accompanied by abdominal pain. Anorexia (anorexia — loss of appetite), constipation, and general dyspepsia are frequently observed.
- Musculoskeletal system: bone marrow stimulation frequently manifests as pain syndrome. The development of myalgia (myalgia — muscle pain) and ossalgia (ossalgia — bone pain) is characteristic.
- Other manifestations: ecchymoses (ecchymoses — extensive hemorrhages into the skin or mucous membranes) and alopecia (alopecia — hair loss) may occur during treatment.
Briefly: answers to topical questions
What dermatological side effects does oprelvekin cause?
During oprelvekin therapy, dermatological manifestations such as alopecia and the formation of ecchymoses are observed on the skin.
For quick memorization of oprelvekin side effects, use the acronym "SKIN" (or the Russian mnemonic): Bones and muscles (ossalgia, myalgia), General (chills, asthenia, nervousness), GI tract (dyspepsia, constipation, anorexia, pain), Alopecia (and ecchymoses).
Class and exam questions
To which pharmacological group does oprelvekin belong?
It is a recombinant growth factor that is structurally and functionally an analogue of human interleukin-11 (IL-11).
What is the ultimate effect of the drug on hematopoiesis?
The drug induces megakaryocyte maturation, ultimately leading to an increased platelet count in the peripheral blood.
In what cases is this drug prescribed to a patient?
It is used in adult patients with non-myeloid malignancies following courses of myelosuppressive chemotherapy when there is a high risk of severe thrombocytopenia.
What musculoskeletal side effects are characteristic of oprelvekin?
Patients may complain of myalgia (pronounced muscle pain) and ossalgia (bone pain).
What else to study on this topic
- Detailed pathogenesis of myelosuppression in chemotherapy for non-myeloid tumors.
- Differences between recombinant interleukin-11 and other hematopoietic growth factors.
- The process of hematopoietic stem cell proliferation and the role of cytokines.
- Stages of megakaryocyte progenitor cell maturation.
- Mechanisms of ossalgia and myalgia development during pharmacologic bone marrow stimulation.
Master the entire topic in the «Pharmacology» course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Oprelvekin" and another 5,304 pages of the subject
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 116 video lessons on the subject
Other topics in the section "Agents Regulating Immune Processes"
Free video lessons: pharmacologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.